惠倫晶體(300460.SZ):副總經理李宗傑違規買賣公司股票
格隆匯8月5日丨惠倫晶體(300460.SZ)公佈,公司近日查詢到公司副總經理李宗傑證券賬户出現違規買賣公司股票的行為。
李宗傑證券賬户於2020年3月30日買入公司股票1000股,成交價格為14.48元/股,成交金額約為1.45萬元,後於2020年4月1日賣出前述全部股票,成交價格為15.00元/股,成交金額約為1.49萬元,前述交易所得收益為422.46元。
經公司與李宗傑確認,李宗傑系中國台灣籍自然人,因未深入理解中國大陸相關法律法規的規定而誤買賣公司股票。截至該公告日,李宗傑及其配偶、父母、子女未持有公司股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.